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To the Editor
Current evidence about COVID-19 symptoms and mortality rate derives from data collected in 
large case series mainly in China, where the virus first emerged, even if the rate of new cases in 
the country has nearly stopped1,2. There are now many more COVID-19 cases outside of China than 
there were inside of it at the height of the outbreak, that is now involving many other countries 
with relevant impact in particular in Spain, United States, and Italy3-5. As of the end of March 2020, 
Italy is the country with the highest number of COVID-19-related deaths with a total of 12428 
deaths and a mortality rate close to 12%6. 
According to the Istituto Superiore di Sanità, Italian epidemiologic data show that patients af-
fected from one to 3 comorbidities and over 70 years are more likely to die due to COVID-19, with a 
male:female ratio of 3:1, and cardiovascular disease is the highest-risk condition7 (Figure 1). These 
data differ from the epidemiologic results observed in other countries where, according to the 
World Meter reports, there is a lower mortality rate (1 to 8%) there is a lower mortality rate than 
Italy and a male: female ratio of 2:18. 
There may be some epidemiologic and social factors might explain the differences between 
Italy and other countries. 
At first, in Italy the majority of elderly patients died at home. Furthermore, these death were 
considered COVID-19 related although test positivity was confirmed post-mortem by nasopharyn-
geal swap. In addition, the nasopharyngeal swap was performed in all patients who died in a 
hospital setting where COVID-19 they were hospitalized. This may have increased the number of 
positive patients that died “with” COVID-19 and not “due to” COVID-19. 
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Figure 1. Type (A) and number (B) of comorbidities found in COVID-19 patients died in Italy according to the Istituto Superiore 
di Sanità7.
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Secondly, the autoptic exam is not generally performed in COVID-19 patients due to the elevate 
number of deaths and the elevate risk of virus transmission through the procedure. Therefore, it is 
difficult to assess other factors that may have caused decease in these patients. 
Thirdly, many COVID-19 patients had one or more comorbidities, especially those over 60 years 
of age7. Comorbidities included hypertension, diabetes, and heart diseases and, along with age, 
certainly play a significant role in mortality rate following COVID-19 infection. Worldwide data 
have shown a mortality rate of 0.9% in patients without comorbidities, that increases progressively 
based on the number of comorbidities and age of the patients9. At the same time, it is well known 
that diseases as hypertension, type-2 diabetes and heart diseases are more prevalent in patients 
over 40 years of age10. These comorbidities could impact the correct function of the cardiovascular 
system and they could be indirectly responsible of the patient’s death11. In Italy, we observed a 
higher mortality rate compared to the Asian population that might be due to the higher prev-
alence of cardiovascular disease in this population. Similarly, the difference in male:female ratio 
between Italy and China reports may be due to the significant higher prevalence of cardiovascular 
diseases in males observed in the Italian population12. 
These hypotheses may explain the differences observed so far between Italian and Asian 
data13,14. However, large case series with further correlations with risk factors, stratified for number 
and type of comorbidities and gender will allow a better epidemiological analysis of these data.
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